Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Blake E. Max

Blake E. Max

Clinical Associate Professor, Pharmacy Practice


Office Phone:

(312) 572-4608 (work)


Related Sites:

Teaching and Supervision Heading link

Spec Project in Pharm Pract (PMPR 390), 1/9/2023 – 4/28/2023
Spec Project in Pharm Pract (PMPR 390), 1/10/2022 – 4/29/2022
Spec Project in Pharm Pract (PMPR 390), 1/11/2021 – 4/30/2021
Management of HIV Patient (PMPR 338), 9/2020 – 1/2021
Spec Project in Pharm Pract (PMPR 390), 1/13/2020 – 5/1/2020
Principles of Drug Action and Therapeutics (PHAR 506), 1/2020 – 5/2020
Co-Course Coordinator Inter-professional collaborative practice in HIV Care PMPR 390, Spring 2020 (PMPR 390), 1/2020 – 4/2020
PDAT 6: Infectious Diseases (PHAR 506), 1/14/2019 – 5/3/2019
Spec Project in Pharm Pract (PMPR 390), 1/14/2019 – 5/3/2019

Selected Grants

AIDS Education and Training Centers, US Department of Health & Human Services (Health Resources and Services Administration)., 9/1/2022 - 8/31/2027, Obligated Amount: $600000; Anticipated Amount: $3000000

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV, National Cancer Institute., 2019 - 2025, Obligated Amount: $15000; No Anticipated Amount Set

Integrating the National HIV Curriculum e-Learning Platform into Health Care Provider Professional Education, US Department of Health & Human Services (Health Resources and Services Administration)., 9/1/2018 - 8/31/2022, Obligated Amount: $2287796; Anticipated Amount: $2400000

Selected Publications

Max, B, DeMarais, P. (2021). Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. International Journal of STD and AIDS, 32, (1), 92-95. doi:10.1177/0956462420964341.

Rock, AE, DeMarais, PL, Vergara-Rodriguez, PT, Max, BE. (2020). HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir. Infectious Diseases and Therapy, 9, (3), 691-696. doi:10.1007/s40121-020-00307-4.

Max, Blake. (2020). I’m not that good with taking pills everyday. What Do I Do Now? – Infectious Diseases. Oxford University Press.

Max, B. (2019). Update on HIV integrase inhibitors for the treatment of HIV-1 infection. Future Virology, 14, (10), 693-709. doi:10.2217/fvl-2019-0077.

Max, Blake, Stevens, B. (2018). Test and Treat: A new model for better patient outcomes. HIV Specialist.

Huesgen, E, DeSear, KE, Egelund, EF, Smith, R, Max, B, Janelle, J. (2016). A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios. Pharmacotherapy, 36, (11), 1145-1165. doi:10.1002/phar.1835.

Max, B, Vibhakar, S. (2014). Dolutegravir: A new HIV integrase inhibitor for the treatment of HIV infection. Future Virology, 9, (11), 967-978. doi:10.2217/FVL.14.80.

Romo, Francine Touzard, Aziz, Mariam, Livak, Britt, Huesgen, Emily, Colton, Ben, Flanigan, Timothy P, Max, Blake, Kessler, Harold. (2014). Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment. Journal of AIDS & Clinical Research, 5, (11). doi:10.4172/2155-6113.1000379.

Huesgen, E, Burgos, R, Goldstein, DA, Max, B, Jarrett, OD. (2012). Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen. Antiviral Therapy, 17, (7), 1385-1388. doi:10.3851/IMP2182.

Professional Leadership

Medical Advisory Board, 2021 - Present

Exam review and question writing, 2021 - Present

American Academy of HIV Medicine (AAHIV) Credentialing Exam Writer, 1/2019 - Present

MATEC Pharmacy Coordinator for Continuing Education, 1/2005 - Present